aid
acquir
immunodefici
syndrom
alt
alanin
aminotransferas
ast
aspart
aminotransferas
cmv
cytomegaloviru
dhf
dengu
hemorrhag
fever
dss
dengu
shock
syndrom
ebv
epsteinbarr
viru
elisa
enzymelink
immunosorb
assay
haart
highli
activ
antiretrovir
therapi
hhv
human
herpesviru
hiv
human
immunodefici
viru
hsv
herp
simplex
viru
igg
immunoglobulin
g
igm
immunoglobulin
ptld
posttranspl
lymphoprolif
diseas
rtpcr
revers
transcript
polymeras
chain
reaction
sar
sever
acut
respiratori
syndrom
vzv
varicellazost
viru
liver
affect
part
gener
host
infect
virus
primarili
target
tissu
liver
involv
nonhepatotrop
viral
infect
rang
mild
derang
liver
biochemistri
fulmin
liver
failur
infect
liver
inflamm
thought
consequ
immun
respons
viral
antigen
rather
direct
hepat
infect
chapter
review
liver
diseas
associ
opportunist
viral
infect
immunocompromis
host
common
system
viral
infect
viral
hemorrhag
fever
tabl
epsteinbarr
viru
ebv
transmit
contact
oral
secret
resid
latent
rest
memori
b
cell
primari
ebv
infect
affect
popul
manifest
classic
triad
fever
sore
throat
lymphadenopathi
known
infecti
mononucleosi
gastrointestin
manifest
abdomin
pain
nausea
diarrhea
mild
ebv
often
caus
mild
selflimit
hepat
manifest
twofold
threefold
elev
level
serum
aminotransferas
hepatosplenomegali
cholestat
biochem
pattern
describ
case
jaundic
rare
case
vanish
bile
duct
syndrom
sporad
sever
hepat
acut
liver
failur
requir
emerg
liver
transplant
rare
acut
liver
failur
case
unit
state
high
casefat
rate
notabl
patient
young
younger
year
immunocompet
clinic
signific
hepat
damag
ebv
infect
occur
immunosuppress
patient
human
immunodefici
viru
hiv
posit
patient
transplant
patient
inflammatori
bowel
diseas
patient
receiv
immunosuppress
medic
chronic
hepat
potenti
link
ebv
infect
report
case
autoimmun
granulomat
hepat
also
associ
ebv
infect
despit
definit
oncogen
potenti
ebv
convinc
evid
link
ebv
develop
liver
cancer
except
lymphoepitheliomalik
hepatocellular
carcinoma
lymphoepitheliomalik
cholangiocarcinoma
ebv
infect
liver
transplant
rare
fear
complic
lead
posttranspl
lymphoprolif
diseas
ptld
adult
ebv
seroposit
predomin
pathophysiolog
mechan
activ
ebv
infect
transplant
ebv
reactiv
highdos
steroid
treatment
reject
strong
predictor
ptld
although
liver
biopsi
sampl
ebv
hepat
patient
exhibit
wide
spectrum
histolog
featur
moder
mark
lymphocyt
infiltr
portal
tract
scatter
foci
interfac
activ
main
find
larg
number
atyp
lymphocyt
present
exclus
hepatosplen
tcell
lymphoma
consid
characterist
featur
ebv
hepat
bead
sinusoid
lymphocyt
infiltr
singlefil
pattern
fig
addit
variabl
degre
bile
duct
damag
seen
case
although
mechan
unknown
small
epithelioid
granuloma
seen
togeth
biliari
histopatholog
featur
biochem
cholestat
pattern
mistakenli
lead
fals
diagnosi
primari
biliari
cholang
diagnosi
ebv
hepat
requir
high
index
suspicion
confirm
ancillari
test
situ
hybrid
polymeras
reduct
immunosuppress
follow
addit
therapi
monoclon
antibodi
rituximab
respons
observ
cytomegaloviru
cmv
ubiquit
herpesviru
depend
popul
studi
infect
human
primari
cmv
infect
immunocompet
individu
present
commonli
asymptomat
ill
benign
infecti
mononucleosislik
syndrom
approxim
case
subclin
selflimit
serum
aminotransferas
elev
present
rare
case
thrombot
complic
portal
vein
thrombosi
buddchiari
syndrom
chain
reaction
pcr
equal
sensit
immunohistochem
stain
ebv
latent
membran
protein
role
ebv
diagnosi
posit
ebv
pcr
situ
hybrid
liver
tissu
discrimin
relev
ebv
infect
occasion
circul
ebvposit
lymphocyt
import
interpret
result
context
histopatholog
chang
ebv
serolog
find
immunoglobulin
igm
immunoglobulin
g
igg
viral
capsid
antigen
epsteinbarr
nuclear
antigen
liver
enzym
level
alter
treatment
ebv
infect
support
infect
selfresolv
week
corticosteroid
acyclovir
clinic
benefit
liver
transplant
ebvrel
acut
liver
failur
effect
initi
treatment
ptld
consist
influenc
outcom
liver
transplant
patient
cmv
diseas
manifest
fever
neutropenia
thrombocytopenia
commonli
endorgan
diseas
pneumonia
retin
central
nervou
system
diseas
hepat
cmv
infect
evid
cmv
replic
regardless
symptom
presenc
diseas
evid
cmv
infect
attribut
sign
symptom
occur
liver
transplant
highrisk
recipi
associ
signific
increas
risk
death
graft
loss
bidirect
relationship
cmv
infect
risk
allograft
reject
cmv
import
etiolog
agent
acquir
immunodefici
syndrom
aid
cholangiopathi
along
cryptosporidium
parvum
common
cholangiogram
find
distal
stenosi
extrahepat
biliari
duct
combin
diffus
irregular
intrahepat
bile
duct
fig
diagnosi
primari
cmv
infect
immunocompet
host
usual
made
serolog
studi
either
detect
cmvspecif
immunoglobulin
igm
fourfold
rise
level
cmvspecif
igg
serolog
test
role
diagnos
cmv
diseas
immunocompromis
patient
quantit
pcr
assay
histopatholog
cmvspecif
immunostain
tissu
biopsi
specimen
use
standard
treatment
cmv
diseas
consist
intraven
administ
ganciclovir
oral
administ
valganciclovir
feasibl
reduct
pharmacolog
immunosuppress
antivir
prophylaxi
preemptiv
therapi
similarli
effect
prevent
cmv
diseas
modestrisk
cmvseroposit
liver
transplant
recipi
wherea
antivir
prophylaxi
prefer
strategi
preemptiv
therapi
prevent
cmv
diseas
highrisk
recipi
cmvseroneg
recipi
liver
allograft
cmvseroposit
donor
herp
simplex
viru
hsv
infect
common
manifest
characterist
oral
hsv
genit
hsv
vesicular
lesion
occasion
accompani
fever
malais
viru
persist
describ
histolog
find
nonspecif
includ
mononuclear
portal
sinusoid
infiltr
increas
hepatocellular
mitot
activ
minim
hepatocellular
necrosi
typic
cmv
nuclear
inclus
cmv
antigen
immunoperoxidas
rare
cmv
describ
caus
acut
granulomat
hepat
immunocompet
patient
fever
unknown
origin
cmv
infect
occur
individu
compromis
immun
liver
transplant
recipi
individu
hiv
infect
malign
associ
substanti
morbid
mortal
infect
liver
transplant
import
entiti
cmv
common
viral
pathogen
rang
absenc
time
diagnosi
treatment
clinic
cours
rapidli
progress
multiorgan
failur
dissemin
intravascular
coagulopathi
death
liver
appear
enlarg
necrot
microscopi
reveal
focal
diffus
hepatocyt
necrosi
characterist
intranuclear
inclus
reveal
hematoxylin
eosin
stain
fig
diagnosi
establish
rapidli
measur
serum
hsv
dna
pcr
serolog
limit
role
igm
presenc
fals
neg
earli
diseas
cours
ill
patient
liver
biopsi
perform
earli
cours
diseas
role
liver
transplant
fulmin
hsv
hepat
controversi
remov
liver
larg
hsv
reservoir
lead
signific
declin
level
viral
dna
extrahepat
diseas
context
posttranspl
immunosuppress
occur
despit
low
undetect
level
hsv
dna
mortal
liver
transplant
hsvrelat
acut
liver
failur
latent
state
ganglion
neuron
reactiv
episod
immunosuppress
stress
hepat
involv
rare
associ
mortal
unlik
smolder
cours
cmv
infect
hsv
hepat
present
fulmin
diseas
usual
fatal
untreat
occur
commonli
immunosuppress
set
transplant
malign
hiv
infect
neonat
period
also
describ
immunocompet
host
clinic
manifest
includ
fever
abdomin
pain
leukopenia
coagulopathi
typic
vesicular
lesion
occur
case
thu
diagnosi
reli
presenc
institut
antivir
prophylaxi
hsv
hepat
solidorgan
transplant
note
within
day
transplant
earlier
cmv
diseas
associ
dissemin
infect
case
serum
aminotransferas
level
elev
time
normal
effect
result
trigger
immunolog
phenomena
transactiv
herpesvirus
cmv
hepat
hhv
hhv
describ
commonli
liver
transplant
recipi
liver
test
valu
elev
mix
pattern
hhv
may
also
associ
liver
allograft
reject
increas
mortal
hhv
associ
reactiv
hhv
cmv
invas
fungal
infect
diagnosi
best
establish
pcr
techniqu
shellvial
cultur
serolog
test
limit
valu
high
seropreval
gener
popul
crossreact
diminish
serolog
reactiv
immunosuppress
individu
treatment
includ
activ
antivir
agent
cmv
infect
ganciclovir
foscarnet
cidofovir
hhv
kaposi
sarcomaassoci
herpesviru
part
human
gamma
herpesvirus
includ
ebv
similarli
play
import
role
cellular
prolifer
develop
malign
hhv
etiolog
agent
kaposi
sarcoma
bodi
caviti
lymphoma
multicentr
castleman
diseas
exact
mode
transmiss
hhv
remain
unclear
potenti
mode
transmiss
includ
saliva
sexual
transmiss
blood
transfus
solid
organ
transplant
preval
hhv
infect
unit
state
unclear
recent
studi
estim
rate
blood
donor
hivseroposit
subject
kaposi
sarcoma
classic
associ
aid
time
common
aid
patient
immunosuppress
host
howev
increasingli
recogn
complic
solid
organ
transplant
incid
unit
state
highest
rate
liver
transplant
recipi
kaposi
sarcoma
repres
malign
transplant
hepat
involv
common
primari
infect
typic
manifest
mild
febril
ill
lymphadenopathi
rash
howev
liver
nodul
part
multiorgan
involv
kaposi
sarcoma
rare
first
manifest
diseas
manifest
includ
characterist
darkr
nodul
present
skin
viscer
organ
whorl
spindleshap
cell
leukocyt
infiltr
neovascular
aberr
prolifer
small
vessel
characterist
microscop
find
fig
castleman
diseas
rare
lymphoprolif
disord
manifest
fever
splenomegali
hepatomegali
massiv
lymphadenopathi
primari
effus
lymphoma
bodi
caviti
lymphoma
specif
subtyp
bcell
lymphoma
relat
hhv
involv
periton
pleural
pericardi
space
diagnosi
base
identif
viral
dna
serum
tissu
pcr
set
hiv
infect
treatment
hhv
diseas
consist
immun
function
restor
highli
activ
antiretrovir
therapi
haart
transplant
recipi
posit
hhv
serolog
find
receiv
organ
donor
posit
serolog
find
monitor
hhv
dna
transplant
strongli
recommend
manag
kaposi
sarcoma
patient
consist
reduct
immunosuppress
regimen
switch
immunosuppress
agent
inhibitor
mammalian
target
rapamycin
sirolimu
everolimu
ganciclovir
foscarnet
cidofovir
effect
vitro
clinic
studi
show
benefit
target
antivir
therapi
limit
valganciclovir
patient
viscer
kaposi
sarcoma
lymphoma
chemotherapi
agent
doxorubicin
daunorubicin
paclitaxel
rituximab
use
success
unclear
mortal
attribut
direct
viral
effect
indirectli
pretranspl
morbid
underli
diseas
predispos
individu
initi
hsv
infect
fulmin
liver
failur
secondari
hsv
diseas
infecti
diseas
emerg
potenti
rapid
progress
death
need
liver
transplant
empir
acyclovir
therapi
patient
present
acut
liver
failur
unknown
caus
recommend
hsv
hepat
exclud
acyclovir
reduc
risk
death
need
liver
transplant
odd
ratio
confid
interv
routin
use
acyclovir
prophylaxi
incid
hsv
infect
solidorgan
transplant
declin
significantli
acyclovir
resist
rare
describ
immunocompromis
individu
primari
varicellazost
viru
vzv
infect
affect
approxim
one
third
us
popul
caus
varicella
chickenpox
manifest
gener
rash
persist
viru
sensori
dorsal
root
ganglia
lead
reactiv
manifest
pain
vesicular
rash
dermatom
distribut
shingl
risk
reactiv
higher
immunocompromis
patient
viscer
organ
involv
rare
document
immunocompromis
patient
hiv
infect
immunosuppress
drug
chemotherapi
transplant
cutan
lesion
eventu
develop
appear
may
delay
liver
histolog
featur
similar
hsv
hepat
diagnosi
made
serum
vzv
pcr
prompt
institut
highdos
intraven
administ
acyclovir
improv
prognosi
patient
diseas
live
attenu
vaccin
licens
prevent
varicella
zoster
contraind
immunosuppress
individu
transplant
recipi
human
herpesviru
hhv
hhv
ubiquit
lymphotrop
virus
genet
biolog
properti
similar
cmv
effect
mediat
immunomodulatori
properti
synergist
effect
virus
acquir
earli
childhood
popul
primari
infect
subclin
diseas
manifest
fever
rash
hhv
caus
roseola
infantum
hhv
associ
pityriasi
rosea
virus
persist
latent
state
reactiv
period
immunosuppress
organ
transplant
critic
illnessrel
stress
similarli
cmv
hhv
caus
fulmin
hepat
neonat
infant
result
mothertochild
transmiss
may
also
account
larg
number
acut
liver
failur
case
unclear
caus
time
diagnosi
valganciclovir
therapi
potenti
avoid
need
liver
transplant
half
patient
receiv
transplant
hhv
fulmin
hepat
show
hhv
recurr
liver
transplant
without
longterm
impact
graft
patient
surviv
incid
infect
hhv
hhv
transplant
rang
respect
adenovirus
common
etiolog
agent
febril
diseas
childhood
common
form
present
acut
upper
respiratori
tract
infect
pharyng
conjunct
pneumonia
enter
describ
adenovir
hepat
rare
present
immunocompromis
host
particularli
pediatr
liver
transplant
recipi
approxim
pediatr
liver
transplant
recipi
develop
adenovir
hepat
second
common
infect
cmv
infect
serotyp
serotyp
commonli
associ
hepat
transmiss
via
liver
allograft
seem
common
viral
reactiv
histolog
featur
includ
circumscrib
foci
necrosi
hepat
lobul
infiltr
monocyt
fig
casefat
rate
high
due
massiv
liver
necrosi
diagnosi
confirm
immunohistochem
stain
viral
cultur
effect
direct
antivir
cidofovir
treatment
limit
signific
nephrotox
tabl
liver
test
abnorm
hivinfect
patient
common
explain
multipl
factor
coinfect
hepatotrop
virus
hepat
b
c
cmv
ebv
opportunist
infect
alcohol
abus
exposur
hepatotox
drug
includ
haart
primari
hiv
infect
rare
manifest
selflimit
hepat
includ
abdomin
pain
hepatomegali
elev
level
serum
aminotransferas
level
sever
hepat
commonli
describ
children
hiv
detect
liver
hepatocyt
kupffer
cell
acceler
viral
replic
context
low
count
level
serum
aminotransferas
highli
elev
time
upper
limit
normal
without
appar
caus
liver
histolog
find
nonspecif
steatohepat
mononuclearlymphocyt
infiltr
common
characterist
immun
restor
haart
decreas
hiv
load
result
normal
liver
test
find
aid
cholangiopathi
rare
condit
character
abnorm
bile
duct
patient
advanc
aid
low
count
hallmark
diseas
cholangiograph
abnorm
includ
papillari
stenosi
scleros
cholang
rare
biliari
strictur
along
cholestat
serolog
pattern
opportunist
infect
cryptosporidium
parvum
microsporidium
cmv
common
caus
account
caus
antimicrobi
treatment
target
agent
resolv
symptom
anatom
abnorm
endoscop
treatment
ampullari
sphincterotomi
balloon
dilat
biliari
strictur
along
haart
main
therapi
gastrointestin
symptom
common
influenza
usual
mild
selflimit
prompt
evalu
thu
preval
liver
test
abnorm
known
southeast
asian
outbreak
avian
influenza
infect
alter
liver
function
test
find
resolv
viral
clearanc
note
patient
aid
congenit
immunodefici
chronic
infect
describ
lack
typic
immunemedi
symptom
rash
arthralgia
manifest
refractori
anemia
organ
damag
hepat
pneumon
myocard
serolog
diagnosi
parvoviru
igm
neg
case
failur
mount
antibodi
diagnosi
reli
pcr
assay
intraven
immunoglobulin
commonli
use
treatment
modal
measl
human
viru
genu
morbilliviru
famili
paramyxovirida
measl
highli
contagi
infect
acquir
childhood
manifest
characterist
rash
symptom
usual
mild
pneumonia
enceph
complic
diseas
cours
transient
liver
enzym
level
elev
common
hepat
manifest
present
adult
measl
may
manifest
jaundic
liver
test
valu
return
normal
within
week
week
histolog
chang
show
necrot
hepatocyt
portal
inflamm
attribut
direct
viral
toxic
persist
measl
viru
genom
implic
pathogenesi
chronic
autoimmun
hepat
diagnosi
commonli
base
serolog
find
antimeasl
igm
detect
day
day
rash
onset
viral
rna
detect
pcr
blood
respiratori
secret
urin
day
rash
appear
measl
vaccin
usual
lead
longterm
immun
vaccin
live
attenu
thu
contraind
pregnant
immunocompromis
host
immunocompromis
patient
expos
measl
receiv
postexposur
prophylaxi
intraven
immunoglobulin
mgkg
regardless
immunolog
vaccin
statu
treatment
support
children
includ
administr
vitamin
rubella
viru
belong
famili
togavirida
rubella
mild
infect
manifest
gener
rash
rare
complic
otiti
media
enceph
arthriti
rubella
pneumonia
evid
influenza
viru
trigger
cellmedi
hepat
absenc
viral
antigen
liver
liver
histolog
find
therefor
nonspecif
extens
hepat
central
lobular
necrosi
among
autopsi
find
fatal
case
outbreak
sever
acut
respiratori
syndrom
sar
coronaviru
etiolog
agent
sever
respiratori
diseas
outbreak
far
east
canada
diseas
casefat
rate
laboratori
abnorm
includ
elev
lactat
dehydrogenas
level
lymphopenia
thrombocytopenia
hypocalcemia
mild
elev
serum
aminotransferas
level
found
almost
patient
initi
present
patient
subsequ
clinic
cours
ribavirin
treatment
fulmin
hepat
failur
describ
patient
moder
mark
liver
test
elev
liver
biopsi
find
includ
mark
mitot
activ
moder
lymphocyt
infiltr
hepatocyt
apoptosi
sar
coronaviru
detect
liver
tissu
revers
transcript
pcr
rtpcr
electron
microscopi
thu
unclear
direct
viral
toxic
explain
hepat
abnorm
effect
therapeut
strategi
sar
develop
antivir
agent
ribavirin
lopinavirritonavir
use
broad
spectrum
activ
rna
virus
hiv
respect
clinic
efficaci
proven
parvoviru
affect
approxim
popul
manifest
mild
includ
fever
myalgia
arthralgia
rash
erythema
infectiosum
sever
complic
includ
aplast
anemia
arthropathi
hepat
manifest
parvoviru
infect
rang
liver
chemistri
abnorm
fulmin
hepat
failur
aplast
anemia
requir
liver
bone
marrow
transplant
infect
pregnanc
lead
abort
due
hydrop
fetali
associ
sever
hepat
immunocompromis
host
posttranspl
infect
describ
part
multisystem
diseas
diagnosi
includ
serolog
rna
detect
pcr
treatment
support
effect
vaccin
yet
avail
tabl
dengu
fever
preval
mosquitoborn
viral
infect
dengu
viru
belong
famili
flavivirida
consist
four
serotyp
aed
aegypti
mosquito
transmiss
vector
endem
area
asia
africa
central
america
south
america
fig
million
infect
known
caus
hepat
dysfunct
except
one
case
neonat
giantcel
hepat
describ
enterovirus
member
famili
picornavirida
transmit
via
fecalor
rout
summer
autumn
month
member
includ
poliovirus
coxsacki
viru
coxsacki
b
viru
echovirus
number
enterovirus
echoviru
echoviru
associ
fulmin
hepat
immunocompromis
adult
liver
histolog
reveal
lymphocyt
inflammatori
infiltr
portal
tract
balloon
hepatocyt
hepat
secondari
coxsacki
b
viru
fig
distribut
global
dengu
fever
risk
high
nonendem
sever
infect
phase
manifest
fever
nonspecif
flulik
symptom
tender
hepatomegali
may
present
serum
transaminas
level
start
rise
hour
hour
onset
ill
appear
jaundic
degre
liver
enzym
abnorm
stage
may
predict
sever
subsequ
hepat
dysfunct
patient
enter
remiss
phase
recov
within
day
howev
patient
enter
intox
phase
character
recurr
fever
hemorrhag
diathesi
multiorgan
dysfunct
stage
mortal
rate
hepat
injuri
reflect
level
aminotransferas
elev
high
ul
ul
level
proport
diseas
sever
alkalin
phosphatas
level
normal
slightli
elev
wherea
direct
bilirubin
level
typic
mgdl
mgdl
higher
level
fatal
case
hepatocyt
apoptosi
result
direct
viral
damag
midzon
liver
lobul
spare
cell
border
central
vein
portal
tract
fig
autopsi
reveal
midzon
hepatocyt
necrosi
mild
nonspecif
lymphocyt
infiltr
eosinophil
degener
councilman
bodi
nonfat
case
heal
complet
without
residu
hepat
abnorm
although
jaundic
liver
enzym
elev
take
week
month
resolv
diagnosi
confirm
presenc
igm
determin
use
enzymelink
immunosorb
assay
elisa
viru
determin
use
pcr
cultur
blood
organ
biopsi
recommend
high
hemorrhag
risk
treatment
support
ribavirin
vitro
activ
yellow
fever
viru
concentr
exceed
clinic
safeti
highli
effect
live
attenu
vaccin
nearli
seroconvers
rate
avail
sinc
offer
travel
nativ
endem
area
live
vaccin
contraind
pregnant
women
immunocompromis
individu
seriou
advers
reaction
vaccin
includ
two
syndrom
yellow
fever
vaccineassoci
neurotrop
diseas
incid
per
yellow
fever
vaccineassoci
viscerotrop
diseas
incid
per
lassa
viru
famili
arenavirida
respons
annual
infect
west
africa
infect
occur
contact
bodi
fluid
infect
multimamm
mice
mastomi
natalensi
via
oral
rout
via
aerosol
infect
mild
asymptomat
clinic
overt
diseas
manifest
case
associ
mortal
rate
incub
period
day
flulik
symptom
associ
nausea
vomit
diarrhea
develop
symptom
associ
increas
vascular
permeabl
central
lassa
fever
pleural
pericardi
effus
facial
edema
bleed
mucos
surfac
recoveri
begin
day
case
infect
progress
pulmonari
edema
encephalopathi
shock
liver
damag
differ
significantli
lassa
fever
gener
key
featur
case
fatal
outcom
lassa
hepat
result
direct
viral
damag
hepatocyt
manifest
elev
level
serum
aminotransferas
commonli
jaundic
coagulopathi
histolog
find
characterist
three
phase
focal
hepatocyt
necrosi
cytoplasm
degener
follow
peak
necrosi
hepatocyt
phagocyt
infiltr
estim
occur
year
worldwid
million
clinic
evid
dengu
fever
increasingli
recogn
frequent
caus
hospit
travel
endem
area
second
malaria
approxim
case
per
travel
although
incid
thought
underestim
infect
asymptomat
present
clinic
featur
dengu
fever
vari
classifi
five
present
nonspecif
febril
ill
classic
dengu
fever
dengu
hemorrhag
fever
dhf
dhf
dengu
shock
syndrom
dss
unusu
syndrom
encephalopathi
acut
liver
failur
onset
symptom
typic
day
mosquito
bite
incub
period
last
longer
day
classic
dengu
fever
manifest
fever
rash
sever
headach
joint
muscl
pain
breakbon
fever
fatigu
infect
selfresolv
support
care
day
convalesc
fatigu
last
week
minor
case
travel
sever
diseas
dhf
dss
occur
widespread
hemorrhag
diseas
like
due
second
infect
differ
dengu
viru
type
lead
heighten
immun
amnest
respons
petechi
hemorrhag
multiorgan
damag
includ
liver
damag
associ
high
morbid
intens
support
care
recommend
especi
dss
massiv
capillari
leak
hypovolem
shock
lead
death
case
hepat
manifest
vari
clinic
sever
dengu
fever
classic
dengu
fever
mild
hepatomegali
elev
level
liver
enzym
mainli
aspart
aminotransferas
ast
occur
patient
attribut
direct
viral
damag
dengu
viru
antigen
isol
hepatocyt
kupffer
cell
sinusoid
endotheli
cell
dhf
dss
tender
hepatomegali
report
patient
direct
viral
damag
hepatocyt
kupffer
cell
lead
multifoc
hemorrhag
patholog
evalu
autopsi
show
hepatocellular
necrosi
minim
inflamm
liver
biopsi
avoid
increas
risk
bleed
confirm
diagnosi
establish
cultur
viru
pcr
test
serolog
assay
howev
signific
limit
sensit
avail
time
present
therefor
diagnosi
made
clinic
symptom
characterist
laboratori
featur
travel
histori
fever
characterist
posit
tourniquet
sign
low
platelet
count
increas
aminotransferas
level
earli
recognit
aggress
support
manag
mainstay
care
vaccin
dengu
viru
avail
yellow
fever
mosquitoborn
viral
hemorrhag
fever
high
casefat
rate
unvaccin
travel
tropic
region
subsaharan
africa
south
america
risk
infect
death
yellow
fever
approxim
infect
africa
includ
death
yellow
fever
prototyp
member
famili
flavivirida
primari
transmiss
cycl
involv
monkey
daytim
bite
mosquito
aed
speci
africa
haemagogu
speci
south
america
classic
ill
character
three
stage
infect
day
remiss
day
intox
hepat
involv
appar
stage
vari
degre
among
virul
human
pathogen
previou
outbreak
describ
central
africa
ebola
epidem
caus
zair
speci
viru
first
occur
west
africa
larger
previou
outbreak
combin
june
case
attribut
ebola
viru
includ
death
natur
reservoir
viru
clearli
defin
bat
seem
least
one
host
viru
transmit
direct
contact
bodi
fluid
infect
anim
blood
bodi
fluid
skin
patient
ebola
viru
diseas
ebola
viru
may
transmit
though
contact
contamin
surfac
object
healthcar
worker
may
risk
ebola
viru
diseas
expos
aerosol
gener
medic
procedur
although
human
case
aerosol
transmiss
report
symptom
occur
incub
period
day
includ
fever
vomit
diarrhea
follow
diffus
maculopapular
rash
select
case
although
infect
previous
categor
hemorrhag
fever
recent
west
recoveri
phase
less
necrot
hepatocyt
hepatocellular
mitos
suggest
liver
regener
laboratori
diagnosi
lassa
fever
reli
detect
viral
antigen
genet
materi
virusspecif
antibodi
method
includ
indirect
fluoresc
antibodi
test
enzymelink
immunosorb
assay
convent
realtim
rtpcr
challeng
accur
time
diagnosi
revolv
around
nonspecif
present
genet
divers
viru
strain
lack
commerci
avail
diagnost
test
treatment
mild
infect
support
intraven
oral
administ
ribavirin
effect
patient
high
mortal
risk
ast
level
iul
highlevel
viremia
greater
efficaci
administ
earli
cours
diseas
effect
vaccin
lassa
viru
ebola
viru
singlestrand
rna
viru
member
famili
filovirida
along
marburg
viru
two
genera
africa
epidem
unexplain
hemorrhag
note
case
hypotens
shock
death
mostli
result
major
fluid
loss
gastrointestin
sourc
liver
diseas
result
multifoc
hepat
necrosi
caus
viru
aminotransferas
elev
ast
higher
alt
suggest
concomit
rhabdomyolysi
mild
elev
alkalin
phosphatas
level
bilirubin
level
characterist
pattern
ebola
viru
diseas
acut
infect
diagnos
viral
rna
detect
use
rtpcr
viru
detect
within
day
onset
symptom
heighten
level
suspicion
risk
stratif
crucial
time
diagnosi
manag
ebola
viru
diseas
treatment
support
approv
medic
treatment
ebola
viru
diseas
approv
postexposur
prophylaxi
vaccin
liver
diseas
associ
opportunist
viral
infect
ubiquit
system
viral
infect
viral
hemorrhag
fever
viral
infect
liver
inflamm
gener
consequ
immun
respons
viral
antigen
rather
direct
hepat
infect
healthi
individu
system
viral
infect
typic
manifest
mild
derang
liver
biochemistri
infect
occur
individu
compromis
immun
liver
transplant
recipi
individu
hiv
infect
malign
associ
substanti
mortal
morbid
includ
acut
liver
failur
treatment
sever
hepat
includ
use
direct
antivir
agent
select
infect
reduct
immunosuppress
applic
liver
transplant
viral
hemorrhag
fever
affect
individu
irrespect
immun
statu
caus
liver
damag
via
direct
viral
hepatotrop
effect
sinc
largest
outbreak
ebola
viru
diseas
histori
develop
west
africa
multipl
organ
includ
center
diseas
control
prevent
world
health
organ
govern
agenc
coordin
extens
effort
control
widespread
transmiss
viru
outbreak
halt
signific
progress
toward
screen
develop
rapid
diagnost
tool
guidanc
regard
travel
isol
effect
decontamin
prevent
humantohuman
transmiss
candid
ebola
vaccin
launch
april
sierra
leon
current
phase
iii
trial
continu
effort
toward
robust
surveil
system
diagnost
strategi
intern
infrastructur
prepar
respond
exist
futur
health
threat
similar
ebola
viru
diseas
undertaken
indirect
consequ
recent
epidem
still
manifest
epidemiolog
genom
clinic
data
continu
collect
analyz
likewis
research
develop
vaccin
effect
treatment
agent
virus
associ
high
motal
morbid
dengu
fever
viru
lassa
fever
viru
yellow
fever
viru
continu
priorit
complet
refer
list
avail
wwwexpertconsultcom
